BTIG Research reiterated their buy rating on shares of Oric Pharmaceuticals (NASDAQ:ORIC – Free Report) in a report published on Tuesday morning, Marketbeat reports. They currently have a $26.00 price target on the stock.
Several other research firms also recently issued reports on ORIC. Stifel Nicolaus increased their target price on Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Wedbush reduced their price target on Oric Pharmaceuticals from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday, October 27th. Finally, HC Wainwright boosted their price objective on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Oric Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $20.18.
Check Out Our Latest Research Report on Oric Pharmaceuticals
Oric Pharmaceuticals Stock Performance
Shares of ORIC stock opened at $7.70 on Tuesday. The firm’s 50 day moving average is $11.17 and its 200 day moving average is $10.95. Oric Pharmaceuticals has a 12 month low of $7.23 and a 12 month high of $14.68.
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.05). On average, equities research analysts predict that Oric Pharmaceuticals will post -1.58 earnings per share for the current year.
Insider Activity at Oric Pharmaceuticals
In related news, CFO Dominic Piscitelli sold 77,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at $955,945.32. This represents a 52.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock valued at $1,432,952 over the last quarter. 5.70% of the stock is owned by insiders.
Institutional Investors Weigh In On Oric Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in ORIC. Algert Global LLC increased its position in shares of Oric Pharmaceuticals by 33.5% in the third quarter. Algert Global LLC now owns 1,621,908 shares of the company’s stock valued at $21,847,000 after acquiring an additional 406,615 shares during the period. New York State Common Retirement Fund raised its stake in shares of Oric Pharmaceuticals by 43.4% during the third quarter. New York State Common Retirement Fund now owns 26,429 shares of the company’s stock valued at $356,000 after acquiring an additional 8,000 shares during the last quarter. Quarry LP boosted its holdings in shares of Oric Pharmaceuticals by 23.9% during the third quarter. Quarry LP now owns 20,848 shares of the company’s stock worth $281,000 after purchasing an additional 4,018 shares during the period. Bellevue Group AG purchased a new stake in shares of Oric Pharmaceuticals during the third quarter worth about $75,000. Finally, Toronto Dominion Bank purchased a new stake in shares of Oric Pharmaceuticals during the third quarter worth about $5,253,000. Institutional investors own 95.05% of the company’s stock.
Key Headlines Impacting Oric Pharmaceuticals
Here are a few of the latest headlines about ORIC:
- Positive Sentiment: BTIG Research reaffirmed its “Buy” rating, and Citigroup was reported to see strong potential for price appreciation. BTIG Research Reaffirms Buy Rating Citigroup Forecasts Strong Price Appreciation
- Neutral Sentiment: Analysts’ reported consensus price target is $21.33, well above the cited $7.70 share price, but a target is an estimate rather than a guarantee. Consensus Price Target
- Negative Sentiment: HC Wainwright cut its target from $27 to $20 while maintaining a “Buy” rating; Wells Fargo lowered its target from $25 to $23 but retained an “Overweight” rating. The reductions may temper optimism, despite both firms remaining bullish. HC Wainwright Rating Wells Fargo Rating
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Recommended Stories
- Five stocks we like better than Oric Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
